| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1464-5491.1999.00190.X |
| P698 | PubMed publication ID | 10656234 |
| P2093 | author name string | H Mehnert | |
| K J Ruhnau | |||
| H J Tritschler | |||
| D Ziegler | |||
| K Schütte | |||
| H P Meissner | |||
| D Nehrdich | |||
| J R Finn | |||
| M Lobisch | |||
| M Reljanovic | |||
| P433 | issue | 12 | |
| P921 | main subject | diabetic polyneuropathy | Q4160985 |
| P304 | page(s) | 1040-1043 | |
| P577 | publication date | 1999-12-01 | |
| P1433 | published in | Diabetic Medicine | Q15758639 |
| P1476 | title | Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy | |
| P478 | volume | 16 |
| Q21285063 | Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials |
| Q44301469 | Alpha lipoic acid changes iron uptake and storage in lens epithelial cells |
| Q24658099 | Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential |
| Q34012029 | Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases |
| Q37329377 | Alpha-lipoic acid supplementation and diabetes |
| Q79218992 | American Association of Clinical Endocrinologists Medical Guidelines for the Clinical Use of Dietary Supplements and Nutraceuticals |
| Q64935458 | Biomarkers of response to alpha-lipoic acid ± palmitoiletanolamide treatment in patients with diabetes and symptoms of peripheral neuropathy. |
| Q44057610 | Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. |
| Q91960932 | Centella asiatica triterpenes for diabetic neuropathy: a randomized, double-blind, placebo-controlled, pilot clinical study |
| Q37895130 | Clinical Approach to the Treatment of Painful Diabetic Neuropathy |
| Q29031018 | Complementary and alternative medicine for the treatment of multiple sclerosis |
| Q34218901 | Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy |
| Q34685307 | Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials. |
| Q45072634 | Diabetic Microvascular Disease: An Endocrine Society Scientific Statement |
| Q44664522 | Diabetic complications. Micro and macroangiopathic end-organ damage |
| Q62673885 | Diabetic neuropathy in older adults |
| Q42165007 | Effect of DHLA on response of isolated rat urinary bladder to repetitive field stimulation |
| Q44495010 | Effects of alpha-lipoic acid on biomarkers of oxidative stress in streptozotocin-induced diabetic rats |
| Q37062946 | Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. |
| Q35087504 | Future treatments for diabetic neuropathy: clues from experimental neuropathy |
| Q51791702 | Long-term safety of alpha-lipoic acid (ALA) consumption: A 2-year study. |
| Q26852079 | Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control |
| Q22241837 | Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development |
| Q42730190 | Monitoring diabetic antioxidant status: a role for in vitro methaemoglobin formation |
| Q34804227 | Neurovascular disease, antioxidants and glycation in diabetes |
| Q35579936 | Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors |
| Q39289330 | Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial |
| Q34733625 | Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives |
| Q34310277 | Pathophysiology of oxidative stress in diabetes mellitus |
| Q36373827 | Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters |
| Q35669992 | Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes |
| Q37017403 | Studies on free radicals, antioxidants, and co-factors |
| Q34292435 | The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society |
| Q35964005 | Treatment with α-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading |
| Q35178801 | Update on the management of diabetic polyneuropathies |
| Q86695248 | [Current therapy of neuropathic pain] |
| Q35579887 | α-Lipoic Acid and Cardiovascular Disease |
Search more.